Aditxt Inc (ADTX) News

Form 8-K - Current report

Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval

Appili has a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense...

Form 8-K - Current report

Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time

Aditxt, Inc. (“Aditxt” “Company”) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, today announced...

Aditxt Completes Third Parent Equity Investment Under Amended and Restated Merger Agreement With Evofem

Aditxt, Inc. (“Aditxt” ) (NASDAQ: ADTX), an innovation platform dedicated to accelerating promising health innovations, and Evofem Biosciences...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Aditxt Delivers Shareholder Update and 2024 Year-End Plan

Acquisition target Evofem reported revenue of $7.8 million for the six months ended June 30, 2024 Acquisition target Appili has received...

Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated to accelerating promising health innovations, announced...

Evofem Biosciences Files Preliminary Proxy for Stockholder Approval of the Acquisition by Aditxt

Companies Targeting Closing in Fourth Quarter of 2024 Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an innovation platform dedicated...

Form 8-K - Current report

Aditxt’s Subsidiary Pearsanta to Collaborate with Evofem Biosciences for Targeted U.S. Launch of Endometriosis Diagnostic in Mid-2025

Endometriosis Affects Approximately 190 Million Women Worldwide Non-invasive MET™ Diagnostic Test for Endometriosis Leverages Novel Biomarker: A...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness